옵션 체인은 다양한 행사가격과 만기일에 대한 Mira Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Mira Pharmaceuticals에 대한 시장 심리를 평가합니다..

Mira Pharmaceuticals (NASDAQ:MIRA) 주식, 옵션 체인

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

LGVN

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

각 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스의 하나인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 7월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보겠다. 현재 가격과 연간 실적은 8월 1일을 기준으로 하며 배당금은 포함되지 않는다. 4월 검색결과는 추적되지 않았다.

단독: 7월 벤징가 프로에서 가장 많이 검색된 상위 20개 종목 - 테슬라, 엔비디아, CRWD 순위는?

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $4 price target.

News

Price Target

Reiteration

Analyst Ratings

HOTH

HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target

<h3>Gainers</h3>
<ul>
<li>Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) shares rose 11.6% to $5.85 during Thursday's pre-market session. The company's market cap stands at $42.6 million. </li>
<li>Society Pass (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) shares increased by 7.56% to $1.28. The market value of their outstanding shares is at $4.6 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) shares rose 5.41% to $0.94. The company's market cap stands at $66.3 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares rose 5.14% to $1.43. The company's market cap stands at $12.4 million. </li>
<li>VS Media Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) shares rose 4.76% to $1.32. The market value of their outstanding shares is at $6.0 million. </li>
<li>Sify Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) stock moved upwards by 4.3% to $3.39. The market value of their outstanding shares is at $1.4 billion. The company's, Q3 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DallasNews (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) stock decreased by 21.8% to $5.21 during Thursday's pre-market session. The market value of their outstanding shares is at $27.8 million. </li>
<li>Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) stock decreased by 15.0% to $121.0. The market value of their outstanding shares is at $31.9 billion. </li>
<li>AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) stock decreased by 14.23% to $19.29. The market value of their outstanding shares is at $3.8 billion. </li>
<li>Star Fashion Culture (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STFS#NASDAQ">STFS</a>) stock fell 10.99% to $2.35. The market value of their outstanding shares is at $28.5 million. </li>
<li>Snail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) stock fell 6.19% to $2.73. The market value of their outstanding shares is at $100.8 million. </li>
<li>MediaCo Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDIA#NASDAQ">MDIA</a>) shares fell 5.67% to $1.0. The company's market cap stands at $46.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASST

ASTS

DALN

MDIA

SIFY

SNAL

SOPA

STFS

VSME

12 Communication Services Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock moved upwards by 35.2% to $0.8 during Thursday's pre-market session. The market value of their outstanding shares is at $6.5 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares rose 25.92% to $0.17. The company's market cap stands at $1.1 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares moved upwards by 23.52% to $12.81. The market value of their outstanding shares is at $38.9 million. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) stock rose 23.15% to $2.5. The market value of their outstanding shares is at $102.1 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares moved upwards by 17.54% to $1.34. The market value of their outstanding shares is at $3.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares moved upwards by 15.2% to $2.5. The company's market cap stands at $130.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock declined by 8.4% to $0.24 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) stock declined by 7.62% to $20.15. The market value of their outstanding shares is at $354.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares fell 7.42% to $0.59. The company's market cap stands at $30.2 million. </li>
<li>Channel Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares declined by 7.04% to $2.51. The company's market cap stands at $15.1 million. </li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) stock declined by 6.62% to $13.7. The market value of their outstanding shares is at $947.5 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 6.43% to $6.99. The market value of their outstanding shares is at $75.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

CHRO

ELTX

ERNA

HEPA

QNRX

RIGL

TNFA

VIGL

XCUR

ZYME

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) stock increased by 13.8% to $22.52 during Thursday's pre-market session. The market value of their outstanding shares is at $671.9 million. As per the news, the Q2 earnings report came out today. </li>
<li>Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) stock moved upwards by 6.17% to $11.34. The market value of their outstanding shares is at $208.3 million. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) stock moved upwards by 5.88% to $1.98. The market value of their outstanding shares is at $10.5 million. </li>
<li>GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) shares moved upwards by 5.86% to $199.41. The market value of their outstanding shares is at $215.8 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) shares increased by 5.35% to $0.94. The market value of their outstanding shares is at $15.2 million. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) shares increased by 5.1% to $0.4. The company's market cap stands at $8.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares decreased by 30.6% to $6.44 during Thursday's pre-market session. The market value of their outstanding shares is at $447.8 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) stock fell 9.09% to $0.5. The market value of their outstanding shares is at $12.6 million. </li>
<li>China Yuchai Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) stock declined by 6.71% to $11.0. The market value of their outstanding shares is at $412.7 million. </li>
<li>American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) shares decreased by 6.22% to $17.5. The market value of their outstanding shares is at $11.4 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares decreased by 5.31% to $1.07. The market value of their outstanding shares is at $19.2 million. </li>
<li>Smart Powerr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) shares declined by 4.43% to $0.6. The company's market cap stands at $5.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BURU

CREG

EVTL

GLXG

LYTS

MYNA

PESI

SPPL

ZCAR

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Kopin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) shares moved upwards by 27.9% to $1.88 during Thursday's pre-market session. The market value of their outstanding shares is at $288.1 million. </li>
<li>U-BX Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares rose 15.75% to $3.38. The company's market cap stands at $11.4 million. </li>
<li>Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) shares moved upwards by 10.22% to $9.38. The company's market cap stands at $105.0 million. </li>
<li>Alpha Modus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>) stock moved upwards by 8.1% to $2.0. The company's market cap stands at $26.4 million. </li>
<li>AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) stock moved upwards by 6.41% to $6.3. The company's market cap stands at $68.8 million. </li>
<li>Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) shares increased by 5.88% to $10.97. The company's market cap stands at $30.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Plexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) stock decreased by 9.2% to $154.9 during Thursday's pre-market session. The company's market cap stands at $4.1 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 9.14% to $0.94. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) stock declined by 9.04% to $1.51. The company's market cap stands at $55.7 million. </li>
<li>Blackboxstocks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBX#NASDAQ">BLBX</a>) shares declined by 8.34% to $5.06. The company's market cap stands at $17.9 million. </li>
<li>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) stock decreased by 7.5% to $2.22. The company's market cap stands at $23.3 million. </li>
<li>Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) shares fell 7.41% to $3.5. The market value of their outstanding shares is at $895.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMOD

AUID

BLBX

BLND

CODA

KOPN

MOBX

NSYS

PLXS

UBXG

VRME

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

The company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology.
"We are very excited by these positive Phase 1 data, which further support continued development of VG-3927 as a potential next-generation therapy for AD," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.&nbsp;
 &nbsp;

Vigil Neuroscience Reports Data From Its Completed Phase 1 Clinical Trial Evaluating VG-3927 For Potential Treatment Of Alzheimer's Disease; Says Candidate Demonstrated Favorable Safety And Tolerability Profile

EVAA Protocol, a lending platform operating on the Ton (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TON</a>) blockchain, on Thursday announced the completion of a private token sale, securing $2.5 million in funding. 
The round saw participation from various venture capital firms, angel investors, and key opinion leaders, including Polymorphic Capital, TON Ventures, and Animoca Ventures.
The capital raised will be used to further develop the protocol&#8217;s infrastructure and expand its footprint within the TON decentralized finance (DeFi) ecosystem. 
Aleksandr Sudeikin, co-founder of EVAA Protocol said, "DeFi technology continues to explode within the TON ecosystem. With our unique product, global community, and financials, we are now in a great position to be a base layer for the whole TON DeFi."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43136512/bitcoin-is-no-threat-to-the-us-dollar-goldman-sachs-ceo-says">Bitcoin Is No &#8216;Threat&#8217; To The US Dollar, Goldman Sachs CEO Says</a>
Since its mainnet launch in early 2024, EVAA has reported attracting 80,000 monthly active users and $50 million in total value locked. The next step in its development will be the launch of its own $EVAA token.
EVAA functions as a lending platform where users can engage in borrowing, lending, shorting, leveraged staking, longing, and hedging. 
The protocol has aligned itself with the TON Foundation's objectives for the growth of the blockchain and DeFi and has plans to reach a wide spectrum of users. 
EVAA is integrated into several platforms such as OKX, Gate, Bitget, Tonkeeper and others. 
Future enhancements include the listing of Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) APY, and listing ecosystem tokens as well. 
The protocol also emphasized user accessibility through its integration with the Telegram messenger app for users managing assets and loans.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43133561/bitcoin-could-drop-up-to-20-as-trump-hope-fades-standard-chartered-warns">Bitcoin Could Drop Up To 20% As Trump &#8216;Hope&#8217; Fades, Standard Chartered Warns</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TON

$USDT

EVAA Protocol Secures $2.5M In Private Token Sale To Expand TON DeFi

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and lowers the price target from $240 to $180.

RGEN

HC Wainwright & Co. Maintains Buy on Repligen, Lowers Price Target to $180

LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.20 by 30 percent. This is a 23.81 percent increase over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $147.734 million which beat the analyst consensus estimate of $129.195 million by 14.35 percent. This is a 35.53 percent increase over sales of $109.005 million the same period last year.

Earnings

Earnings Beats

LSI Industries Q2 2025 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $147.734M Beat $129.195M Estimate

First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) reported quarterly adjusted earnings of $0.46 per share which beat the analyst consensus estimate of $0.41 by 12.2 percent. This is a 6.12 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $241.50 million which beat the analyst consensus estimate of $236.55 million by 2.09 percent. This is a 22.79 percent increase over sales of $196.68 million the same period last year.

First BanCorp Q4 Adj $0.46 Beats $0.41 Estimate, Sales $241.50M Beat $236.55M Estimate

WIIM

American Airlines shares are trading lower following weak Q1 and FY25 guidance.

Old Republic Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.70 by 28.57 percent. This is a 30.43 percent increase over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $2.156 billion which beat the analyst consensus estimate of $2.113 billion by 2.01 percent. This is a 11.08 percent increase over sales of $1.941 billion the same period last year.

Old Republic Intl Q4 2024 Adj. EPS $0.90 Beats $0.70 Estimate, Sales $2.156B Beat $2.113B Estimate

Guidance

American Airlines Sees Q1 Adj. EPS $(0.40)-$(0.20) vs $(0.04) Est., FY25 Adj. EPS $1.70-$2.70 vs $2.42 Est.

Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.14 by 7.14 percent. This is a 40.91 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $474.18 million which beat the analyst consensus estimate of $468.00 million by 1.32 percent. This is a 5.38 percent increase over sales of $449.97 million the same period last year.

Earnings Misses

Valley Ntl Q4 2024 Adj EPS $0.13 Misses $0.14 Estimate, Sales $474.18M Beat $468.00M Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $80 price target.

ARWR

HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $80 Price Target

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) with a Overweight rating and announces Price Target of $93.

Initiation

DRUG

Piper Sandler Initiates Coverage On Bright Minds Biosciences with Overweight Rating, Announces Price Target of $93

The collaboration will provide businesses across Europe with seamless, hardware-free access to vehicle telematics data, enabling smarter fleet management and operational efficiencies.

STLA

Samsara Enters Integration With Mobilisights, The Data As A Service Company Of Stellantis

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.57, a high estimate of $99.00, and a low estimate of $88.00. Observing a 2.26% increase, the current average has risen from the previous average price target of $91.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1737633652_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of MetLife by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MetLife. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MetLife compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MetLife analyst ratings.</a>
<h2>About MetLife</h2>
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
<h3>Unraveling the Financial Story of MetLife</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 16.6%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MetLife's net margin is impressive, surpassing industry averages. With a net margin of 6.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): MetLife's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.39% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.18%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 0.61, MetLife faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: MetLife In The Eyes Of 7 Experts

5 analysts have expressed a variety of opinions on Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Primerica, presenting an average target of $322.2, a high estimate of $345.00, and a low estimate of $300.00. This upward trend is apparent, with the current average reflecting a 3.35% increase from the previous average price target of $311.75.
<img src="https://www.benzinga.com/files/images/story/2025/1737633643_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Primerica's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$311.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$315.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Andrew Kligerman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Primerica. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Primerica compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Primerica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Primerica's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Primerica analyst ratings.</a>
<h2>Delving into Primerica's Background</h2>
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has four segments Term Life Insurance; Investment and Savings Products; Senior Health; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the US.
<h3>Primerica's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Primerica's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Primerica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Primerica's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.11%, the company showcases effective utilization of assets.
Debt Management: Primerica's debt-to-equity ratio stands notably higher than the industry average, reaching 1.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Primerica Through The Eyes Of 5 Analysts

American Airlines Group Q4 2024 Adj. EPS $0.86 Beats $0.64 Estimate, Sales $13.7B Beat $13.395B Estimate

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MIRA Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is seeing massive gains on Monday after the pre-clinical-stage pharmaceutical company released data from its pre-clinical study of Ketamir-2.



Ketamir-2. is MIRA Pharmaceuticals&rsquo; novel oral ketamine analog. It&rsquo;s being studied as a potential <a href="https://finance.yahoo.com/news/mira-pharmaceuticals-reveals-preclinical-success-120000778.html">treatment for neurological and neuropsychiatric disorders</a>. That includes depression, treatment-resistant depression and post-traumatic stress disorder (PTSD).



Here&rsquo;s what MIRA Pharmaceuticals chairman and CEO Erez Aminov said about the new data.




&ldquo;Our vision at MIRA is to transform the treatment landscape for neurological and neuropsychiatric disorders. Ketamir-2 shows great promise in addressing these debilitating conditions with improved efficacy and safety, offering new hope and better quality of life for patients and their families. Importantly, we are seeing a drumbeat of promising data this year that we hope will allow us to file an IND and begin to test our theories about Ketamir-2 in actual patients in the near term.&rdquo;




<h2>What This Means for MIRA Stock</h2>



MIRA stock could benefit greatly if the company is able to move forward with its IND plans. The company&rsquo;s shares are already gaining today with more than 116 million shares traded. For the record, its daily average trading volume is about 654,000 shares.



MIRA Stock is up 318.1% as of Monday afternoon.



Investors will want to stick around for more of the most recent stock market stories!



We have all of the hottest stock market news investors need to know about on Monday! Among that is what has shares of Nio&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/nio-stock-quote/">NIO</a>), Reddit&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/rddt-stock-quote/">RDDT</a>) and Cassava Sciences&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sava-stock-quote/">SAVA</a>) stock moving today. All of that info is good to go at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/nio-stock-alert-more-details-emerge-about-upcoming-nio-day-2024/">NIO Stock Alert: More Details Emerge About Upcoming Nio Day 2024</a></li>



<li><a href="https://investorplace.com/2024/07/rddt-stock-alert-reddit-nabs-new-deals-with-nfl-nba/">RDDT Stock Alert: Reddit Nabs New Deals with NFL, NBA</a></li>



<li><a href="https://investorplace.com/2024/07/sava-stock-alert-cassava-sciences-pops-on-late-stage-trial-update/">SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!



Moving stocks this morning are earnings reports, a settlement agreement, the pricing of a public offering and more.



Let&rsquo;s get into that below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is rocketing close to 254% alongside heavy pre-market trading.</li>



<li>Nature&rsquo;s Miracle (NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>) shares are soaring more than 122% with strong early morning trading.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is surging nearly 78% with heavy early morning trading today.</li>



<li>Frequency Electronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/feim-stock-quote/">FEIM</a>) shares are rising almost 33% alongside its <a href="https://www.marketwatch.com/story/frequency-electronics-shares-climb-on-higher-4q-earnings-a32189da">Q4 earnings report</a>.</li>



<li>Mammoth Energy Services (NASDAQ:<a href="https://investorplace.com/stock-quotes/tusk-stock-quote/">TUSK</a>) stock is heading over 29% higher after <a href="https://www.nasdaq.com/press-release/cobra-acquisitions-llc-announces-settlement-agreement-prepa-2024-07-22">announcing a settlement agreement</a>.</li>



<li>ENGlobal (NASDAQ:<a href="https://investorplace.com/stock-quotes/eng-stock-quote/">ENG</a>) shares are gaining more than 22% without any clear news.</li>



<li>Wheeler Real Estate IT (NASDAQ:<a href="https://investorplace.com/stock-quotes/whlr-stock-quote/">WHLR</a>) stock is jumping over 20% with no news to report.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are climbing more than 19% despite a lack of news on Tuesday.</li>



<li>SCYNEXIS (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) stock is getting an over 15% boost on a <a href="https://www.nasdaq.com/press-release/scynexis-receive-10-million-milestone-payment-gsk-triggered-delivery-completed-furi">$10 million milestone payment</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) shares are up more than 13% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock is crashing more than 59% after <a href="https://www.nasdaq.com/press-release/transcode-therapeutics-inc-announces-pricing-public-offering-2024-07-22">pricing a public offering</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are plummeting close to 31% <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">after a massive rally yesterday</a>.</li>



<li>Brera (NASDAQ:<a href="https://investorplace.com/stock-quotes/brea-stock-quote/">BREA</a>) stock is diving nearly 25% with strong pre-market trading this morning.</li>



<li>CareMax (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmax-stock-quote/">CMAX</a>) shares are tumbling over 22% <a href="https://www.benzinga.com/news/24/07/39892411/caremax-shares-are-up-by-more-than-200-what-you-need-to-know">after a rally yesterday</a>.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) stock is taking a more than 19% beating after a recent rally.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are sliding over 19% <a href="https://investorplace.com/2024/07/why-is-castellum-ctm-stock-moving-today/">alongside volatility yesterday</a>.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is falling almost 16% as shares <a href="https://investorplace.com/2024/07/why-is-exicure-xcur-stock-down-27-today/">continue to come off a recent rally</a>.</li>



<li>Quoin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/qnrx-stock-quote/">QNRX</a>) shares are dropping more than 15% today.</li>



<li>Polaris (NYSE:<a href="https://investorplace.com/stock-quotes/pii-stock-quote/">PII</a>) stock is slipping over 15% after <a href="https://www.marketwatch.com/story/polaris-stock-tumbles-11-after-earnings-fall-far-short-of-consensus-and-company-cuts-full-year-outlook-c3299335">missing earnings estimates</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares close out our pre-market stock movers down more than 14%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-23rd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) stock is down on Tuesday as the clinical-stage pharmaceutical company&rsquo;s shares come off of a major rally on Monday.



Shares of MIRA stock closed out Monday&rsquo;s normal trading hours up 627.4%. That came alongside heavy trading with <a href="https://finance.yahoo.com/quote/MIRA/">more than 153 million shares traded</a>. For comparison, its daily average trading volume is about 3.2 million shares.



Mira Pharmaceuticals stock experienced this rally after releasing data from a <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-up-318-today/">pre-clinical study of Ketamir-2</a>. This is the company&rsquo;s novel oral ketamine analog designed to treat neurological and neuropsychiatric disorders.



The big news here is that the results were positive. This has the company excited about the prospect of furthering the development of Ketamir-2 and submitting an investigational new drug (IND) application for it.



<h2>MIRA Stock Movement on Tuesday</h2>



Considering the massive rally MIRA shares underwent yesterday, it makes sense they would give up some of those gains in the days to follow. This has the stock dropping 27.4% as of Tuesday morning.



Today&rsquo;s dip comes with more than 5.5 million shares changing hands this morning. That&rsquo;s already above its daily average trading volume but is well below yesterday&rsquo;s heavy trading.



Investors who are seeking out even more of the most recent stock market stories today will want to keep reading!



We have all of the hottest stock market news that traders need to know about on Tuesday! That includes everything happening with shares of TransCode Therapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) stock, Nature&rsquo;s Miracle&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/nmhi-stock-quote/">NMHI</a>)&nbsp;stock and Warrantee&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-transcode-therapeutics-rnaz-stock-down-62-today/">Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-sentinelone-s-stock-amid-cybersecurity-carnage/">Trade of the Day: Buy SentinelOne (S) Stock Amid Cybersecurity Carnage</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-natures-miracle-nmhi-stock-up-94-today/">Why Is Nature&rsquo;s Miracle (NMHI) Stock Up 94% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-mira-pharmaceuticals-mira-stock-down-27-today/">Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

Earnings Week Ahead: Walmart, Home Depot, Alibaba, Cisco and more

MIRA Mira Pharmaceuticals files $100M mixed securities shelf

MIRA Pharmaceuticals files $100M mixed securities shelf

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) just reported results for the second quarter of 2024.<ul><li>Mira Pharmaceuticals reported earnings per share of -11 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mira-stock-earnings-mira-pharmaceuticals-for-q2-of-2024/">MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an update. MIRA Pharmaceuticals, Inc. announces a significant leadership change as Michael Jerman...

MIRA Pharmaceuticals Appoints New Board Member and Chairman

MIRA Pharmaceuticals (MIRA), has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for Ketamir-2, its nove...

MIRA Pharmaceuticals submits IND to FDA for Ketamir-2

In this edition of "Rising High," The Fly conducted an exclusive interview with Erez Aminov, Chairman & Chief Executive Officer of MIRA Pharmaceuti...

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌